Valuation: EnteroMedics Inc

Market Cap 1.42Cr 1.26Cr 1.19Cr 1.08Cr 2.02Cr 136.72Cr 2.04Cr 14Cr 5.5Cr 70Cr 5.35Cr 5.23Cr 224.66Cr P/E 2026 *
-3.72x
P/E 2027 * -2.54x
Enterprise Value 1.42Cr 1.26Cr 1.19Cr 1.08Cr 2.02Cr 136.72Cr 2.04Cr 14Cr 5.5Cr 70Cr 5.35Cr 5.23Cr 224.66Cr EV / Sales 2026 *
130x
EV / Sales 2027 * 71.2x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 1L 96.63T 91.43T 82.92T 2L 1.05Cr 2L 10.97L 4L 53.65L 4L 4L 1.73Cr 2L 2L 2L 2L 3L 1.92Cr 3L 20.03L 8L 98L 8L 7L 3.15Cr
Net income -38L -33.53L -31.73L -28.78L -53.95L -36Cr -54.48L -3.81Cr -1.47Cr -19Cr -1.43Cr -1.4Cr -60Cr -78.46L -69.24L -65.51L -59.41L -1.11Cr -75Cr -1.12Cr -7.86Cr -3.03Cr -38Cr -2.95Cr -2.88Cr -123.72Cr
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-